Joshua Yang co-founded Glyphic Biotechnologies with the mission to fundamentally change the underlying engine of biomedical discovery through development and commercialization of a next-generation protein sequencer.
He is an inventor on six issued/filed patents and author on 18 research articles as of October 2021. He was named to the Forbes 30 Under 30 Healthcare list in 2021.
Josh earned his BS from UC San Diego, his Master of Translational Medicine from UC Berkeley and UCSF, and his MBA from the Stanford Graduate School of Business. He is on leave of absence from the combined MD-PhD program at the Johns Hopkins University School of Medicine.